Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
Haemophilia · 2026
DOI: 10.1111/hae.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Midori Shima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Product Surveillance, Postmarketing. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Introduction
The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018.
Aim
To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who initiated emicizumab within 1 year of availability.
Methods
This all‐case post‐marketing surveillance (PMS) study was conducted between May 2018 and January 2023, in patients of all ages and HA severities. Patients were registered retrospectively after emicizumab initiation or prospectively at the time of initiation. Adverse events (AEs) and adverse drug reactions (ADRs), including thromboembolic events (TEs) and thrombotic microangiopathy (TMA), and their association with BPA use, were examined. FVIII inhibitor levels and annualised bleeding rates (ABRs) were evaluated.
Results
In total, 134 patients were included in the analysis. Mean (standard deviation) duration of emicizumab treatment was 145.5 (34.8) weeks. Overall, 112 AEs occurred in 47 patients (35.1%) and 22 ADRs occurred in 12 patients (9.0%); 8 ADRs (36.4%) were serious. No TEs/TMAs associated with concomitant use of BPAs occurred. FVIII inhibitor levels remained stable or decreased for 34 patients (55.7%). Sixty‐eight patients (50.7%) received BPAs; none received activated prothrombin complex concentrate. Mean (95% confidence interval) model‐based all bleed ABR and treated bleed ABR were 1.4 (0.9–2.3) and 1.3 (0.8–2.1), respectively.
Conclusion
This study comprises 3 years’ PMS for emicizumab. No TEs/TMA associated with BPAs occurred. Results further support the safety and effectiveness of emicizumab in Japanese patients with congenital HA with inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan.
- Department of Pediatrics, Nara Medical University, Kashihara, Japan.
- Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
- Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
- Department of Hematology, Nara Medical University, Kashihara, Japan.
- Drug Safety Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
ORCID-Profile: Midori Shima
Förderung
- Chugai Pharmaceutical Co., Ltd
Zitieren
APA
Shima, M., Fukutake, K., Matsumoto, M., Sugimura, Y., Sugita, C., Ji, L., Kawano, M., & Matsushita, T. (2026). Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors. Haemophilia. https://doi.org/10.1111/hae.70162
Vancouver
Shima M, Fukutake K, Matsumoto M, Sugimura Y, Sugita C, Ji L, et al. Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors. Haemophilia. 2026. doi:10.1111/hae.70162
BibTeX
@article{Shima2026,
author = {Shima, Midori and Fukutake, Katsuyuki and Matsumoto, Masanori and Sugimura, Yoshihiko and Sugita, Chiaki and Ji, Lyu and Kawano, Mika and Matsushita, Tadashi},
title = {Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70162}
}
EUVIMED